<b>Conclusions:</b> These findings explain the inconsistent efficacy of 11β-HSD1 inhibitors in AD patients by revealing an APOE4-dependent activation of HSD11B1 that promotes early EC pathology. This evidence concerns the gene HSD11B1 and Alzheimer disease.